Evidence map›Paper›PMID 40135845›Full record

ArticleJournal of cosmetic dermatology2025

Adipogenic Effect of Magnolol in Primary Human Pre-Adipocytes With Potential Skin Health and Volumizing Effect.

Alan D Widgerow, Nava Dayan, Mary E Ziegler, Faiza Shafiq

Abstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alan D WidgerowDivision Chief Research, Professor Plastic Surgery, Center for Tissue Engineering, University of California, Irvine, California, USA.
Nava DayanNava Dayan Ltd, Shoham, Israel.
Mary E ZieglerAlastin Skincare, Inc, A Galderma Company, Fort Worth, Texas, USA.
Faiza ShafiqAlastin Skincare, Inc, A Galderma Company, Fort Worth, Texas, USA.

Funding

Galderma laboratories, Fort Worth
6 · The paper itself

Abstract

backgroundAging is associated with fat atrophy and fibrosis with loss of adipocyte differentiation from preadipocytes. New approaches to this loss involve agents that can renew the proliferative and differentiative capacities of preadipocytes with the aim of creating new healthy adipose tissue that secrete adipokines that positively impact on skin health. MATERIAL &

methodsWe investigated the effect of Magnolol (ML), a naturally derived compound, on human primary pre-adipocyte viability and proliferation as well as adipogenic gene expression and increase in lipid production. Cell proliferation was assessed using fluorescent signaling, and adipocyte differentiation was monitored by following morphological and microscopic changes. RNA purification and real-time PCR were undertaken to examine gene expression changes, and Oil red O staining was used to confirm adipose cell transformation. Adipokine expression, in particular adiponectin quantification, was also undertaken.

resultsMagnolol, at a relatively low concentration, demonstrated clear adipogenic activity: with a significant increase in preadipocyte proliferation after 48 h and a significant accumulation of adipocytes as demonstrated by oil red staining. Increased gene expression of PLN1 and FABP4 and a significant increase in adiponectin protein expression was demonstrated.

conclusionMagnolol stimulates preadipocyte proliferation and conversion to adipokine-producing adipocytes. This has the potential for a positive skin health and volumizing effect if used in a topical formulation.

Indexed as

AdipocytesAdipogenesisBiphenyl CompoundsLignansAdiponectinCell DifferentiationCell ProliferationCells, CulturedCell SurvivalFatty Acid-Binding ProteinsHumansAdiponectinBiphenyl CompoundsFABP4 protein, humanFatty Acid-Binding ProteinsLignansmagnololadipogenesisadiponectinCCAAT/enhancer‐binding protein alpha (c/EBPα)fatty acid binding protein 4 (FABP4)magnolol (ML)perilipin (PLIN)peroxisome proliferator‐activated receptor (PPARγ)subcutaneous white adipose tissue (sWAT)

Identifiers

PMID40135845
PMCPMC11938804

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.